Venture capital-backed gene therapy specialist uniQure has raised nearly $82m via an IPO on the Nasdaq exchange, which was priced above the indicative range.
The Amsterdam-based company was floated at a price of $17 per share, raising $81.9m. The IPO price was above the expected range of $13 to $15 per share.
UniQure’s backers include Advent Venture Partners, Coller Capital and Forbion Capital Partners.
UniQure’s first product, Glybera, was approved by the European Commission in October 2012 for the treatment of patients with lipoprotein lipase deficiency.
Glybera is expected to be commercially launched in some European countries in the first half of this year via the company’s partnership with Chiesi Farmaceutici, which was signed in April last year.
In August and December last year the company held meetings with the US Food and Drug Administration and it plans to file an investigational new drug application in the US this year.
In November one of uniQure’s investors, Advent, made a €1.17bn cash offer for Dutch business software company UNIT4.
Copyright © 2014 AltAssets